|PositiveID to accelerate breath glucose detection system testing and prototype development|
|By Staff and Wire Reports|
|Monday, 14 June 2010 08:50|
PositiveID Corporation (NASDAQ:PSID) announced today that it has achieved an important milestone in the development of its non-invasive Easy Check breath glucose detection system. The Company has completed the development of a single-use capsule containing a proprietary chemical reagent that it believes will enable it to accelerate its development schedule and produce a lab-scale prototype device during the third quarter of 2010. Through the use of the capsule and proprietary chemical mixture contained therein, the prototype is expected to be able to measure the levels of acetone in a patient’s exhaled breath, which, in turn, will be translated into a measurement of blood glucose levels. This could eliminate a patient’s need to prick his or her finger multiple times per day to get a blood sugar reading.
Continued research and development efforts of the Company’s scientific team, based in Israel, have led to the initial design completion of the Easy Check chemical sensor, a single-use capsule that contains a proprietary chemical reagent, which mixes with the volatile organic chemicals in a patient’s exhaled breath to create a chemical reaction that is measured by the device’s optical density sensors. The readings are immediately translated by the device's software into blood glucose measurements that are expected to correlate closely to glucose readings obtained by conventional blood glucose measuring devices. The new capsule measures approximately five centimeters in length.
Scott R. Silverman, Chairman and CEO of PositiveID, said, “This development breakthrough enables us to significantly accelerate our efforts to design a lab-scale prototype of our patent-pending Easy Check breath-based glucose detection system and conduct laboratory-based comparisons of the non-invasive Easy Check breath glucose analysis system versus the current standard 'finger stick' blood glucose testing method. We will continue our work over the summer on our lab-scale prototype and if successful, we believe initial testing of the first miniaturized, handheld Easy Check device could start as early as the end of 2010.”
According to a November 2009 study by researchers at the University of Chicago published in the journal Diabetes Care, the number of diabetics in the U.S., which currently stands at 23.7 million, may almost double in 25 years, and the annual cost of treating them may triple to $336 billion.
About PositiveID Corporation
PositiveID Corporation develops and markets healthcare and information management products through its RFID-based diagnostic devices and identification technologies, and its proprietary disease management tools. PositiveID operates in two main divisions: HealthID and ID Security. For more information on PositiveID, please visit www.PositiveIDCorp.com.